Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China

Park

Clinical Laboratory Analysis

et al. 2018

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer

Park

Clinical Laboratory Analysis

et al. 2018

Clinical Laboratory Analysis

“…In recent years, some articles reported that HE4 cut-off values set to less than 140 pmol/l is appropriate. Those research showed that the HE4 cut-off value was not only related to menopause, but also associated with ethnic origin (35)(36)(37)(38)(39)(40)(41)(42)(43)(44). Recently, Roche, together with nine major Chinese hospitals, started a multicenter clinical study with a large number of samples on the new diagnosis of the ovarian cancer tumor marker HE4.…”

Section: Discussionmentioning

confidence: 99%

The Establishment of an HE4‐CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer

Zhang

Wang

et al. 2016

“…Over the past decade, HE4 has gained widespread use as an effective tumor marker in the diagnosis of OC. Numerous clinical studies have demonstrated significant elevations of serum HE4 levels in patients with gynecological cancer and have confirmed that HE4 levels may be used as a biomarker for OC with higher specificity than the widely used CA-125 (4,7,8,(10)(11)(12). A previous study observed that HE4 had sensitivity of 72.9% and specificity of 95% in the differential diagnosis of OC and benign ovarian masses (13).…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, early diagnosis of OC is a key factor in improving patient survival. Currently, tumor markers, such as the human epididymis protein 4 (HE4) (5) and carbohydrate antigen-125 (CA-125) (6), and the risk of ovarian malignancy algorithm (ROMA) and risk malignancy index (RMI) (7)(8)(9) are important tools for the differential diagnosis of patients with abdominopelvic masses.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic value of urinary-to-serum human epididymis protein 4 ratio in ovarian cancer

Fan

Luo

et al. 2017

Biomedical Reports

Abstract. Human epididymis protein 4 (HE4) is one of the best-known tumor markers for ovarian cancer (OC). Emerging evidence indicates that the evaluation of serum HE4 (S-HE4) levels may be problematic when patients have chronic kidney disease (CKD). Assaying urine for HE4 levels is non-invasive alternative for the diagnosis of OC. However, whether the combined detection of S-and urinary HE4 (U-HE4) levels distinguishes OC from CKD remains unknown. To investigate this issue, the present study recruited 31 female patients with OC, 38 female patients with CKD, and 36 healthy control (HC) females. Serum and urine samples were preoperatively collected for HE4 level detection. Receiver operating characteristic (ROC) curves were constructed to assess the diagnostic performance of S-HE4 level, U-HE4 level and the ratio of urinary-to-serum HE4 level (R-HE4). Data from the current study indicated that serum HE4 levels in the OC and CKD groups were significantly higher than that in the HC group. The U-HE4 level in the OC group was significantly higher than that in the CKD and HC groups. The highest R-HE4 was observed in the HC group, followed by the OC group, and the lowest R-HE4 was observed in the CKD group. ROC analysis demonstrated that the R-HE4 was useful in differentiating OC from CKD and HC. Based on the diagnostic interval of optimal cut-off values from 36.85 to 96.15, the sensitivity and specificity of R-HE4 in differentiating OC patients from non-OC patients were 82.6 and 85.4%, respectively. Thus, the combined detection of S-and U-HE4 levels facilitates the diagnosis of OC, and R-HE4 is an effective marker for differentiating OC from CKD.